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OBJECTIVES: To estimate the prevalence of potentially significant drug-drug inter-
actions (DDIs) among ambulatory elderly residents of the Local Health Authority
(LHU) of Parma, Italy, and to identify possible predictors of DDIs. METHODS: We
conducted a retrospective cohort study using the 2009 Parma LHU outpatient phar-
macy database of 86,571 elderly subjects aged 65 years who had at least one
prescription filled during the study year (92.4% of the total elderly). Potentially
significant DDIs were determined using a previously published list, which was
updated to include a final list of 17 drug pairs according to the drugs reimbursed by
the 2009 Italian National Formulary. A potentially significant DDI was defined as
the presence of aminimum5-day overlap in days supply for drugs in an interacting
pair. The prevalence estimate was measured over a 1-year period and reported as
the total number of exposures per 10,000 subjects. Logistic regression was used to
identify patient characteristics as possible predictors of DDIs. RESULTS: An overall
1,218 elderly were exposed to a total of 1,279 potentially significant DDIs, yielding a
1-year period prevalence of 148 exposures per 10,000 subjects. The most common
DDIs were warfarin and NSAIDS (47 per 10,000), simvastatin/lovastatin and amio-
darone (45 per 10,000), and simvastatin/lovastatin and macrolides (30 per 10,000).
Odds of exposure were significantly higher among those aged 75-84 years and
thosewithmore chronic conditions, while odds of exposurewere lower in females.
Risk of exposure increased 1.23 times for each additional prescribed drug.
CONCLUSIONS:Our results revealed that a substantial number of DDIs occurred in
the elderly outpatients of Parma LHU, especially in the chronically ill subjects.
Findings should be disseminated to general practitioners to increase the aware-
ness of potentially significant DDIs and characteristics associated with an in-
creased risk of exposure to ensure safe, effective, and appropriate use of medica-
tion for their elderly patients.
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IMPACT OF THE FDA’S ANTIPSYCHOTIC BLACK BOX WARNING ON
PSYCHOTROPIC DRUG PRESCRIBING IN ELDERLY PATIENTS WITH DEMENTIA
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OBJECTIVES:Most patients with dementia also suffer from Behavioral and Psycho-
logical Symptoms of Dementia (BPSD). BPSD is a major reason for accelerated cog-
nitive decline and poor functioning in dementia patients, institutionalization, and
increased caregiver distress, and hence poses a significant quality-of-life and eco-
nomic burden on patients and their families. There is currently no FDA-approved
treatment for BPSD. Our objectives were: To determine (1)whether the FDA’s Black
Box warning in April 2005 has led to a decline in off-label prescriptions of atypical
antipsychotics for BPSD as well as (2) whether prescriptions for other psychotropic
drugs, including acetylcholinesterase inhibitors (ACIs), antidepressants, anxiolyt-
ics, and antiepileptics have increased. METHODS: Data were obtained and com-
bined from two large national surveys: the National Ambulatory Medical Care Sur-
vey and the National Hospital AmbulatoryMedical Care Survey. Visits of elderly (
65) patients with dementia were identified using the International Classification of
Disease, 9th Revision, Clinical Modification (ICD-9 CM) codes for dementia. Ex-
cluded were the visits for which the patient had a diagnosis of schizophrenia or
bipolar disorder. Percentage drug utilization statistics were calculated. RESULTS:
The percentage of visits mentioning an atypical antipsychotic decreased from
12.5% pre-warning to 11.5% post-warning. The percent utilization of ACIs, antide-
pressants, and anxiolytics has fallen, while the use of antiepileptics has remained
the same since the FDA’s warning. Post-warning, 34.4% of patients were taking
none of the study medications, as opposed to 26.1% pre-warning. In 2005, the year
of the warning, 44.6% of visits had no study-drug mention. CONCLUSIONS: Our
findings suggest that the FDA’s April 2005 Black Box warning had just a small
negative impact on the use of atypical antipsychotics. There is no evidence of
substitution of other psychotropic medications for the atypicals. What are needed
are FDA-approved drugs for BPSD so that prescriber choices can expand beyond
off-label options.
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THE LONG TERM UTILIZATION OF STIMULANTS IN CHILDREN AND
ADOLESCENTS: A MEDICAID STUDY
Sudharshan L, Chen H
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OBJECTIVES: To assess the long term stimulant use and other psychotropic med-
ications for a 4-17 age group that received a stimulant prescription in 1995. The
secondary objective was to examine the factors associated with long term stimu-
lant use.METHODS:A retrospective longitudinal analysis was conducted using the
1995-2001Medicaid claims data. Patients that received a prescription of a stimulant
in 1995 were followed through 2001 to determine the duration of stimulant use,
defined as percentage that received a prescription of stimulant every year of the
study period. Long term stimulant use is defined as the duration in years of con-
tinuous stimulant use, measured as a beneficiary receiving at least one prescrip-
tion of Dextroamphetamine,Methylphenidate or Pemoline per year. Amultivariate
linear regression model was employed to identify the factors associated with the
long-term use of stimulants. RESULTS: Out of 5,022 subjects who received a pre-
scription of at least one stimulant in 1995, 1,985 (39.52%) patients continued to take
stimulants at the end of 7 years. Almost one third of the cohort had at least one
psychiatric disorder during the study period. ADHD (Attention-deficit/hyperactiv-
ity disorder) was the most common psychiatric disorder seen in 1,950 (98.23%) of
the recipients. Being white, young age at baseline, having ADHD and comorbid
substance use disorder, use of antianxiety, antidepressants, anticonvulsants, al-
pha agonists and antipsychotic medications as well as physician specialty (psychi-
atrist/psychologist vs. other specialties), county of recipient (rural vs. metropoli-
tan) and hospitalization due to psychotic disorders were significantly (p 0.05)
associated with the long term use of stimulants. CONCLUSIONS: More than one
third of patients who receive stimulants as children continue receiving stimulants
at the end of 7 year follow-up. Patients who continuously used stimulants during
the 7 year follow-up had higher psychiatric co-morbidities and took more psycho-
tropic co-medications.
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OBJECTIVES: Influenza clinical trials usually focus on outcomes such laboratory
confirmed infection using viral culture and/or rise in antibody titers to influenza
antigens. However, new agents are not only expected to reduce infection but in-
fection intensity. Symptom severity and duration symptoms such as fever, cough,
malaise, functional impact, and time to return to daily activities have increased
importance. The aim was to develop and validate a Patient Reported Outcomes
(PRO) measure of the intensity and impact of influenza infection.METHODS: Con-
sistent with US Food and Drug Administration guidelines, construct and item gen-
eration were guided by the literature and consultation with patients and expert
physicians through concept mapping, focus groups, and interviews. Items were
administered to 311 people with influenza like illness (ILI) across 25 USA sites with
random assignment to paper or electronic interactive voice response system
(IVRS). Analyses included classical psychometrics, structural equation modeling
(SEM) and Rasch analyses. RESULTS: A total of 149 concepts covering the influenza
experience were derived from concept mapping and these clustered into Symp-
toms and Impact on Daily activities, Emotions and Others. Impact scales were
unidimensional whereas the symptoms domain factored into Systemic and Respi-
ratory symptoms. All domains displayed good internal consistency (Cronbach
0.8) except the 3-item Respiratory domain (0.48). A six-factor SEM indicated
excellent fit where Systemic, Respiratory and Daily activities domains differenti-
ated patients with ILI or confirmed influenza. All scales were responsive over time.
SEM indicated paper and IVRS data could be pooled. CONCLUSIONS: The use of
FDA-recommended procedures for patient and clinician consultation, robust psycho-
metrics, and evaluation of the items and domains in the target population, has gen-
erated rigorous data to support the validity of the FluiiQ. The FluiiQ should improve
evaluation of existing and future agents designed to prevent or control influenza in-
fection by increasing the breadth and depth of measurement in this field.
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ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR
PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT
Gao X1, Ji X2, Stephens JM1, Schlamm H3, Tarallo M3
1Pharmerit International, Bethesda, MD, USA, 2Pharmerit North America, LLC, Bethesda, MD,
USA, 3Pfizer, Inc., New York, NY, USA
OBJECTIVES: To assess the association between drug tolerability and economic
impact for prophylaxis of invasive fungal infection (IFI) after allogeneic hemato-
poietic stem cell transplant (HSCT). METHODS: A prospective open-label multi-
center study (IMPROVIT) for primary IFI prophylaxis after HSCT included patients
12 years who were randomized to receive oral voriconazole(VOR) or oral itra-
conazole(ITR) from HSCT day for at least 100 and up to 180 days. Data for the first
100 days were analyzed. Medical resource use (MRU) endpoints were valued with
2010 UK costs. Univariate, multivariate, and subgroup analyses were conducted.
RESULTS: 224 patients were in the VOR and 241 in the ITR group, with similar
demographic distributions (average age 43-year, 59% male, 92% Caucasian). All-
cause and study drug intolerance discontinuations were less frequent with VOR
than ITR (73% vs 82%, p0.02; 7% vs 22%, p0.0001). VOR patients had longer study
drug exposure (median: 96 vs 68 days, p0.0001; mean: 68 vs 60 days, p0.0162).
Multiple regression showed that ITR patientswere 2 timesmore likely (P0.0032) to
use concomitant antifungals (AF) versus VOR patients. Controlling for treatment
and key baseline variables, prophylaxis duration was associated with all key MRU:
longer IFI prophylaxis was associated with fewer hospital days (p0.0001), special
unit days (p0.0001), and less concomitant AF use (p0.0001). Consequently, treat-
ment exposure was negatively associated with total cost (p0.0001) and concom-
itant AF cost (p0.0035). Patients who had study discontinuation or concomitant
AF use incurred 74% (£ 26,972 vs £ 15,484, p0.0001) and 56% (£ 41,775 vs. £ 26,782,
p0.0001) higher total cost, compared to their counterparts respectively. Eight
more prophylaxis days were associatedwith approximately 1 less hospital day and
5% total cost reduction. Subgroup analyses showed similar results.CONCLUSIONS:
The ability of patients to tolerate and continue their AF prophylaxis after HSCT
appears to be associated with significant economic consequences.
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